Holen Sie sich die Stockscreener-App
375.43
0.41%
-1.54
Handel nachbörslich:
374.00
-1.43
-0.38%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$376.97
Offen:
$376.17
24-Stunden-Volumen:
2.28M
Relative Volume:
0.81
Marktkapitalisierung:
$202.38B
Einnahmen:
$36.74B
Nettoeinkommen (Verlust:
$7.71B
KGV:
26.38
EPS:
14.2333
Netto-Cashflow:
$8.10B
1W Leistung:
-0.42%
1M Leistung:
+2.96%
6M Leistung:
+34.80%
1J Leistung:
+14.68%
1-Tages-Spanne:
$372.74
$379.26
1-Wochen-Bereich:
$361.39
$380.09
52-Wochen-Spanne:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, NVS, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
375.43 | 203.21B | 36.74B | 7.71B | 8.10B | 14.23 |
|
LLY
Lilly Eli Co
|
1,001.35 | 900.48B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.71 | 584.62B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.01 | 402.17B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
161.59 | 310.63B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.99 | 302.33B | 58.80B | 10.24B | 8.98B | 3.2788 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-20 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-05 | Hochstufung | Erste Group | Hold → Buy |
| 2025-11-24 | Fortgesetzt | Truist | Hold |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-03 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Crysvita Market Is Going to Boom | Kyowa Kirin • Amgen • Sanofi • Takeda Pharmaceutical - openPR.com
Rep. David Taylor Sells Off Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
SNL mocks Amgen’s Otezla in bizarre sketch featuring Ryan Gosling - Medical Marketing and Media
Amgen Named to Forbes’ 2026 List of America’s Best Large Employers - Amgen
9 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus - TradingView
Swiss National Bank Sells 77,600 Shares of Amgen Inc. $AMGN - MarketBeat
The first KRAS drugs have been sluggish on the market. Will the next generation fare better? - Pharma Voice
Therapeutics Companies Exceed Q4 2025 Revenue Estimates, Led by Novavax and AmgenNews and Statistics - IndexBox
Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks - Finviz
First Trust Advisors LP Sells 46,048 Shares of Amgen Inc. $AMGN - MarketBeat
Better Weight Loss Stock: Novo Nordisk Vs. Amgen - The Globe and Mail
Better Weight Loss Stock: Novo Nordisk Vs. Amgen - The Motley Fool
Amgen Inc. (AMGN) Completes Phase 3 Trial for ABP 206 Opdivo Biosimilar Candidate - Yahoo Finance
Vinva Investment Management Ltd Increases Holdings in Amgen Inc. $AMGN - MarketBeat
Korea Investment CORP Sells 22,072 Shares of Amgen Inc. $AMGN - MarketBeat
Blair William & Co. IL Reduces Position in Amgen Inc. $AMGN - MarketBeat
B. Metzler seel. Sohn & Co. AG Has $14.48 Million Stake in Amgen Inc. $AMGN - MarketBeat
Assessing Amgen (AMGN) Valuation After Rocatinlimab Trial Halt And Pipeline Setback - simplywall.st
56,522 Shares in Amgen Inc. $AMGN Bought by Munich Reinsurance Co Stock Corp in Munich - MarketBeat
Neuberger Berman Group LLC Sells 3,315 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
3,603 Shares in Amgen Inc. $AMGN Purchased by Integrity Advisory Solutions LLC - MarketBeat
Pitcairn Co. Reduces Stock Position in Amgen Inc. $AMGN - MarketBeat
Wearable Injectors Market Set to Witness Rapid Growth Through - openPR.com
Edgar Lomax Co. VA Sells 29,960 Shares of Amgen Inc. $AMGN - MarketBeat
American Century Companies Inc. Raises Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Xgeva Market Booming with Rapid Growth Through 2033 | Amgen • Novartis • Pfizer • Eli Lilly - openPR.com
AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE - Amgen
Kyowa Kirin discontinues rocatinlimab trials due to safety issues - bioworld.com
Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities - Yahoo Finance
Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report? - Yahoo Finance
Amgen Inc Stock (AMGN) Moved Down by 3.08% on Mar 5: Key Drivers Unveiled - TradingKey
Amgen Inc. (NASDAQ:AMGN) Plans Quarterly Dividend of $2.52 - MarketBeat
Amgen: Wait For A Better Entry Point (Rating Downgrade) (NASDAQ:AMGN) - Seeking Alpha
ARK Investment Management LLC Sells 10,668 Shares of Amgen Inc. $AMGN - MarketBeat
CI Investments Inc. Has $6.34 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Rocatinlimab Halt Puts Spotlight On Amgen Pipeline Mix And Valuation Gap - simplywall.st
Is Amgen (AMGN) Pricing Reflect Its Recent 24% One Year Share Price Return - Yahoo Finance
Amgen (AMGN) Maintains Quarterly Dividend of $2.52 Per Share - GuruFocus
Amgen Keeps Quarterly Dividend at $2.52 a Share, Payable June 5 to Holders of Record May 15 - marketscreener.com
AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND - Amgen
Amgen announces 2026 second quarter dividend - marketscreener.com
Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial - TipRanks
Dimensional Fund Advisors Boosts Amgen Holdings - National Today
Smith Chas P & Associates PA Cpas Sells 47,455 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Victory Capital Management Inc. - MarketBeat
Mcdonald Partners LLC Decreases Holdings in Amgen Inc. $AMGN - MarketBeat
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
Dimensional Fund Advisors LP Raises Holdings in Amgen Inc. $AMGN - MarketBeat
Is It Time To Reassess Amgen (AMGN) After Its Strong Multi Year Share Price Run? - simplywall.st
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.32%
2.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):